{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:44:00Z","timestamp":1785386640053,"version":"3.55.0"},"reference-count":110,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) is a highly heterogeneous disease arising from acquired genetic and epigenetic aberrations which stifle normal development and differentiation of hematopoietic precursors. Despite the complex and varied biological underpinnings, induction therapy for AML has remained fairly uniform over 4 decades and outcomes remain poor for most patients. Recently, enhanced understanding of the leukemic epigenome has resulted in the translational investigation of a number of epigenetic modifying agents currently in various stages of clinical development. These novel therapies are based on mechanistic rationale and offer the potential to improve AML patient outcomes. In light of many recent advances in this field, we provide an updated, clinically oriented review of the evolving landscape of epigenetic modifying agents for the treatment of AML.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001245","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T16:19:56Z","timestamp":1583770796000},"page":"970-982","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Clinical developments in epigenetic-directed therapies in acute myeloid leukemia"],"prefix":"10.1182","volume":"4","author":[{"given":"Darren","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"first","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"first","affiliation":[{"name":"Adult Leukemia Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"issue":"1","key":"2020032011195872500_B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"2020032011195872500_B2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2009-03-211003","article-title":"Quantitative DNA methylation predicts survival in adult acute myeloid leukemia","volume":"115","author":"Bullinger","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2020032011195872500_B3","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/leu.2017.109","article-title":"Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape","volume":"31","author":"Silva","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"2020032011195872500_B4","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat Med"},{"issue":"22","key":"2020032011195872500_B5","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2020032011195872500_B6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020032011195872500_B7","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2020032011195872500_B8","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1128\/MCB.25.11.4727-4741.2005","article-title":"5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal [published correction appears in Mol Cell Biol. 2018;38(10). pii: e00539-17]","volume":"25","author":"Ghoshal","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2020032011195872500_B9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"issue":"2","key":"2020032011195872500_B10","doi-asserted-by":"crossref","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"2020032011195872500_B11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/leu.2008.397","article-title":"The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells","volume":"23","author":"Flotho","year":"2009","journal-title":"Leukemia"},{"issue":"35","key":"2020032011195872500_B12","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"issue":"4","key":"2020032011195872500_B13","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0021-9258(19)68144-5","article-title":"Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2\u2032-deoxycytidine","volume":"257","author":"Creusot","year":"1982","journal-title":"J Biol Chem"},{"issue":"3","key":"2020032011195872500_B14","doi-asserted-by":"crossref","first-page":"e17388","DOI":"10.1371\/journal.pone.0017388","article-title":"Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines","volume":"6","author":"Hagemann","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"2020032011195872500_B15","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","article-title":"Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2032-deoxycytidine (decitabine) treatment","volume":"100","author":"Daskalakis","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2020032011195872500_B16","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1158\/0008-5472.CAN-05-2385","article-title":"DNA methylation changes after 5-aza-2\u2032-deoxycytidine therapy in patients with leukemia","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"2020032011195872500_B17","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1586\/era.09.61","article-title":"Azacitidine for the treatment of myelodysplastic syndrome","volume":"9","author":"Cataldo","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"24","key":"2020032011195872500_B18","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1002\/cncr.24661","article-title":"Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities","volume":"115","author":"Ravandi","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"2020032011195872500_B19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020032011195872500_B20","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020032011195872500_bib111","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Blood"},{"issue":"13","key":"2020032011195872500_B21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2020032011195872500_B22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/fon.15.326","article-title":"Design of the randomized, phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia","volume":"12","author":"Roboz","year":"2016","journal-title":"Future Oncol"},{"key":"2020032011195872500_B23","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood-2019-132405","article-title":"The QUAZAR AML-001 Maintenance Trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020032011195872500_B24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncr.31138","article-title":"Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia","volume":"124","author":"Roboz","year":"2018","journal-title":"Cancer"},{"issue":"22","key":"2020032011195872500_B25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood.V128.22.904.904","article-title":"Long term survival and clinical complete responses of various prognostic subgroups in 103 relapsed\/refractory acute myeloid leukemia (r\/r AML) patients treated with guadecitabine (SGI-110) in phase 2 studies","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2020032011195872500_B26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","article-title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial","volume":"18","author":"Kantarjian","year":"2017","journal-title":"Lancet Oncol"},{"key":"2020032011195872500_B27","unstructured":"Otsuka and Astex announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naive AML patients ineligible to receive intense induction chemotherapy. Available at: https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2018\/20180731_1.html. Accessed 20 May 2019."},{"issue":"18","key":"2020032011195872500_B28","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020032011195872500_B29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2015.265","article-title":"Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Garcia-Manero","year":"2016","journal-title":"Leukemia"},{"key":"2020032011195872500_B30","first-page":"4274","article-title":"A phase 2 dose-confirmation study of oral ASTX727, a combination of oral decitabine with a cytidine deaminase inhibitor (CDAi) cedazuridine (E7727), in subjects with myelodysplastic syndromes (MDS)","volume":"130","author":"Garcia-Manero","year":"2017","journal-title":"Blood"},{"key":"2020032011195872500_B31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2019-122980","article-title":"Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine\/decitabine) compared to IV decitabine","volume":"134","author":"Garcia-Manero","year":"2019","journal-title":"Blood"},{"issue":"16","key":"2020032011195872500_B32","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"2020032011195872500_B33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.leukres.2015.03.006","article-title":"Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up","volume":"39","author":"Cabrero","year":"2015","journal-title":"Leuk Res"},{"issue":"9","key":"2020032011195872500_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2020032011195872500_B35","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"issue":"1","key":"2020032011195872500_B36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2020032011195872500_B37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","article-title":"Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study","volume":"53","author":"Al-Ali","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2020032011195872500_B38","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.1200\/JCO.2017.35.15_suppl.7026","article-title":"Phase IB\/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML)","volume":"35","author":"Daver","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020032011195872500_B39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjh.14463","article-title":"Elevated fetal haemoglobin is a predictor of better outcome in MDS\/AML patients receiving 5-aza-2\u2032-deoxycytidine (decitabine)","volume":"176","author":"L\u00fcbbert","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"2020032011195872500_B40","doi-asserted-by":"crossref","first-page":"E77","DOI":"10.1002\/ajh.23965","article-title":"Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia","volume":"90","author":"Emadi","year":"2015","journal-title":"Am J Hematol"},{"issue":"7","key":"2020032011195872500_B41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"2020032011195872500_B42","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/leu.2011.342","article-title":"DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia","volume":"26","author":"Metzeler","year":"2012","journal-title":"Leukemia"},{"issue":"21","key":"2020032011195872500_B43","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2020032011195872500_B44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00277-010-0921-5","article-title":"Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment","volume":"89","author":"Moon","year":"2010","journal-title":"Ann Hematol"},{"issue":"4","key":"2020032011195872500_B45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","article-title":"Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy","volume":"19","author":"Mahfouz","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020032011195872500_B46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cncr.22376","article-title":"Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"2020032011195872500_B47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.leukres.2014.12.013","article-title":"Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction","volume":"39","author":"Ramos","year":"2015","journal-title":"Leuk Res"},{"issue":"2","key":"2020032011195872500_B48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020032011195872500_B49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?","volume":"4","author":"Johnstone","year":"2003","journal-title":"Cancer Cell"},{"issue":"1","key":"2020032011195872500_B50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nm1161","article-title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells","volume":"11","author":"Nebbioso","year":"2005","journal-title":"Nat Med"},{"issue":"32","key":"2020032011195872500_B51","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020032011195872500_B52","doi-asserted-by":"crossref","first-page":"e20987","DOI":"10.1371\/journal.pone.0020987","article-title":"Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells","volume":"6","author":"Petruccelli","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"2020032011195872500_B53","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2005-09-008086","article-title":"Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor","volume":"108","author":"Sanchez-Gonzalez","year":"2006","journal-title":"Blood"},{"issue":"22","key":"2020032011195872500_B54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood.V128.22.901.901","article-title":"SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML)","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020032011195872500_B55","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat Genet"},{"issue":"7","key":"2020032011195872500_B56","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/ng.3889","article-title":"DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats [published correction appears in Nat Genet. 2017;49(11):1661]","volume":"49","author":"Brocks","year":"2017","journal-title":"Nat Genet"},{"issue":"21","key":"2020032011195872500_B57","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1158\/1078-0432.CCR-17-1423","article-title":"Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature","volume":"23","author":"Craddock","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2020032011195872500_B58","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020032011195872500_B59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1586\/14737140.2015.1047770","article-title":"Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma [published correction appears in Expert Rev Anticancer Ther. 2015;15(9):1121]","volume":"15","author":"Richardson","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"2020032011195872500_B60","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4161\/cbt.8.10.8213","article-title":"Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells","volume":"8","author":"Fiskus","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2020032011195872500_B61","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1038\/bcj.2013.68","article-title":"Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"4","author":"Tan","year":"2014","journal-title":"Blood Cancer J"},{"issue":"12","key":"2020032011195872500_B62","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u226430% blasts","volume":"31","author":"Garcia-Manero","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"2020032011195872500_B63","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020032011195872500_B64","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.V126.23.453.453","article-title":"Final results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML)","volume":"126","author":"Garcia-Manero","year":"2015","journal-title":"Blood"},{"key":"2020032011195872500_B65","first-page":"2581","article-title":"Safety and clinical activity of combined romidepsin and azacitidine therapy in high risk acute myeloid leukemia: preliminary results of the Romaza Trial","volume":"130","author":"Craddock","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020032011195872500_B66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"7390","key":"2020032011195872500_B67","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"4","key":"2020032011195872500_B68","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ccell.2015.03.009","article-title":"Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia","volume":"27","author":"Shih","year":"2015","journal-title":"Cancer Cell"},{"issue":"49","key":"2020032011195872500_B69","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/onc.2010.444","article-title":"Cancer-associated IDH mutations: biomarker and therapeutic opportunities","volume":"29","author":"Yen","year":"2010","journal-title":"Oncogene"},{"issue":"22","key":"2020032011195872500_B70","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020032011195872500_B71","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2020032011195872500_B72","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2020032011195872500_B73","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"2020032011195872500_B74","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1200\/JCO.2019.37.15_suppl.7028","article-title":"Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): updated results from a phase 1 study","volume":"37","author":"Roboz","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020032011195872500_B75","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2018-99-110449","article-title":"Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions","volume":"132","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"2020032011195872500_B76","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1158\/1538-7445.AM2018-4956","article-title":"Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model","volume":"78","author":"Yen","year":"2018","journal-title":"Cancer Res"},{"key":"2020032011195872500_B77","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1200\/JCO.2018.36.15_suppl.7042","article-title":"Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML)","volume":"36","author":"Dinardo","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020032011195872500_B78","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood-2019-130362","article-title":"Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: interim phase II results from an ongoing, randomized study","volume":"134","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020032011195872500_B79","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol Cell"},{"issue":"7327","key":"2020032011195872500_B80","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"6","key":"2020032011195872500_B81","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"40","key":"2020032011195872500_B82","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7370","key":"2020032011195872500_B83","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"issue":"19","key":"2020032011195872500_B84","doi-asserted-by":"crossref","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Coud\u00e9","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"2020032011195872500_B85","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"key":"2020032011195872500_B86","first-page":"1377","article-title":"A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I\/II open label single agent study in patients with acute myeloid leukemia (AML)","volume":"130","author":"Dawson","year":"2017","journal-title":"Blood"},{"key":"2020032011195872500_B87","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1200\/JCO.2018.36.15_suppl.7019","article-title":"First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed\/refractory (RR) acute myeloid leukemia (AML): preliminary data","volume":"36","author":"Borthakur","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020032011195872500_B88","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood-2019-124741","article-title":"Phase 1 dose escalation and expansion study to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of the BET inhibitor FT-1101 as a single agent in patients with relapsed or refractory hematologic malignancies","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020032011195872500_B89","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-018-0165-5","article-title":"Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells","volume":"9","author":"Fiskus","year":"2019","journal-title":"Blood Cancer J"},{"key":"2020032011195872500_B90","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2019-128618","article-title":"Selective targeting BET family Bdii bromodomain with Abbv-744 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models","volume":"134","author":"Cai","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2020032011195872500_B91","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","article-title":"Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells","volume":"13","author":"Fiskus","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2020032011195872500_B92","first-page":"75","article-title":"Histone lysine methylation and demethylation pathways in cancer","volume":"1815","author":"Varier","year":"2011","journal-title":"Biochia Biophys Acta"},{"issue":"13","key":"2020032011195872500_B93","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells","volume":"114","author":"Fiskus","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2020032011195872500_B94","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1046\/j.1365-2141.2001.02641.x","article-title":"The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma","volume":"112","author":"Visser","year":"2001","journal-title":"Br J Haematol"},{"issue":"13","key":"2020032011195872500_B95","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM199309233291302","article-title":"Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations","volume":"329","author":"Thirman","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"2020032011195872500_B96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"issue":"1","key":"2020032011195872500_B97","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"issue":"13","key":"2020032011195872500_B98","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1073\/pnas.1202258109","article-title":"Polycomb repressive complex 2 is required for MLL-AF9 leukemia","volume":"109","author":"Neff","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2020032011195872500_B99","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/leu.2017.300","article-title":"Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia","volume":"32","author":"Fujita","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2020032011195872500_B100","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2020032011195872500_B101","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"issue":"22","key":"2020032011195872500_B102","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V128.22.2780.2780","article-title":"Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia","volume":"128","author":"Shukla","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2020032011195872500_B103","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2020032011195872500_B104","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"issue":"21","key":"2020032011195872500_B105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V124.21.267.267","article-title":"Pharmacological inhibitors of LSD1 promote differentiation of myeloid leukemia cells through a mechanism independent of histone demethylation","volume":"124","author":"Lynch","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020032011195872500_B106","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nm.2661","article-title":"Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia","volume":"18","author":"Schenk","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"2020032011195872500_B107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","article-title":"Protein arginine methylation in mammals: who, what, and why","volume":"33","author":"Bedford","year":"2009","journal-title":"Mol Cell"},{"issue":"9","key":"2020032011195872500_B108","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1172\/JCI81749","article-title":"Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis","volume":"125","author":"Liu","year":"2015","journal-title":"J Clin Invest"},{"issue":"10","key":"2020032011195872500_B109","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/ncb1642","article-title":"Protein arginine-methyltransferase-dependent oncogenesis","volume":"9","author":"Cheung","year":"2007","journal-title":"Nat Cell Biol"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2020001862","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/5\/970\/1719873\/advancesadv2019001245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/5\/970\/1719873\/advancesadv2019001245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T01:48:03Z","timestamp":1666057683000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/5\/970\/452668\/Clinical-developments-in-epigeneticdirected"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001245","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2020001862","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]}}}